According to IMARC Group’s latest report, titled “Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026.’ The global canine atopic dermatitis market reached a value of US$ XX Million in 2020. Canine atopic dermatitis (CAD) is an allergic, inflammatory skin disease in dogs caused by environmental allergens such as grass, mold spores, and house dust mites. It is highly prevalent in German shepherds, Labradors, golden retrievers and pugs aged six months to three years. It is characterized by symptoms including excessive itching, scratching, skin inflammation, and rubbing and licking, majorly around the face, paws, and underarms. In addition, food ingredients and other insect bites can also trigger the symptoms in dogs.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report
Request for a PDF sample of this report: https://www.imarcgroup.com/canine-atopic-dermatitis-market/requestsample
The market is primarily driven by the rising incidences of atopic dermatitis in dogs triggered due to air pollution and allergens. In addition, the growing awareness among pet owners about early signs and symptoms of allergic reaction and the increasing adoption of pet insurance is positively influencing the market growth. Furthermore, the rapid development of advanced therapeutic methods to control symptoms in animals represents another key factor driving the global market. Moreover, rising environmental factors responsible for allergies and increasing research and development (R&D) investment by the key industry players in the field of veterinary sciences are anticipated to propel the market growth in the upcoming years. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026.
- AB Science
- Bimeda Inc.
- Bioceltix SA
- Boehringer Ingelheim International GmbH
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Elanco Animal Health Incorporated
- Phibro Animal Health Corporation
- Toray Industries Inc.
- Vetoquinol S.A.
- Virbac and Zoetis Inc.
Key Market Segmentation:
Breakup by Drug Class Type:
- Monoclonal Antibody
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Veterinary Hospitals
- Pet Clinics
- Pharmacies and Drugstores
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Explore full report with TOC & List of Figures: https://bit.ly/308ylpQ
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800